Literature DB >> 19487439

Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model.

Aude A Ferran1, Anne-Sylvie Kesteman, Pierre-Louis Toutain, Alain Bousquet-Mélou.   

Abstract

Maintaining quinolone concentrations outside the mutant selection window (MSW) between the MIC and mutant prevention concentration (MPC) was suggested by in vitro and in vivo studies to prevent the selection of resistant mutants. However, selection also may depend on the presence of resistant bacterial mutants at the start of treatment, which is highly dependent on the initial inoculum size. In this study, a mouse thigh bacterial infection model was used to test the influence of different exposures to marbofloxacin on the selection of resistant bacteria after infection with a low (10(5) CFU) or high (10(8) CFU) initial inoculum of Escherichia coli. The inoculum size was shown to influence the exposure to marbofloxacin and the values of pharmacokinetic/pharmacodynamic indices. When the abilities of the indices time within the MSW (T(MSW)), area under the concentration-time curve of 0 to 24 h divided by the MIC, and the maximum concentration of drug in plasma divided by the MIC to predict the selection of resistant bacteria were compared, only T(MSW) appeared to be a good predictor of the prevention of resistance for values less than 30%. When the T(MSW) was higher than 34%, the selection of resistant bacteria occurred less often in thighs initially infected with the low inoculum (11/24; 46%) than in those infected with the high inoculum (30/36; 80%), suggesting that the selection of resistant mutants depends on both the T(MSW) and inoculum size. The relevance of these results merits further investigation to test different strategies of antibiotic therapy depending on the expected bacterial burden at the infectious site.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487439      PMCID: PMC2715583          DOI: 10.1128/AAC.01347-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.

Authors:  Aude Ferran; Véronique Dupouy; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

2.  Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.

Authors:  Alexander A Firsov; Maria V Smirnova; Elena N Strukova; Sergey N Vostrov; Yury A Portnoy; Stephen H Zinner
Journal:  Int J Antimicrob Agents       Date:  2008-09-14       Impact factor: 5.283

Review 3.  Effects of bacterial endotoxin on drug pharmacokinetics.

Authors:  T Hasegawa; K Takagi; K Kitaichi
Journal:  Nagoya J Med Sci       Date:  1999-05       Impact factor: 1.131

Review 4.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Authors:  X Zhao; K Drlica
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

5.  In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

6.  Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model.

Authors:  Amy Sarah Ginsburg; Ronggai Sun; Heather Calamita; Cherise P Scott; William R Bishai; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

8.  Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus.

Authors:  Jeffrey J Campion; Philip Chung; Patrick J McNamara; William B Titlow; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

9.  Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.

Authors:  Stephen H Zinner; Irene Yu Lubenko; Deborah Gilbert; Kelly Simmons; Xilin Zhao; Karl Drlica; Alexander A Firsov
Journal:  J Antimicrob Chemother       Date:  2003-09-01       Impact factor: 5.790

10.  Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.

Authors:  Delphine Croisier; Manuel Etienne; Emilie Bergoin; Pierre-Emmanuel Charles; Catherine Lequeu; Lionel Piroth; Henri Portier; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more
  14 in total

1.  Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lung infection in rats.

Authors:  Anne-Sylvie Kesteman; Agnès Perrin-Guyomard; Michel Laurentie; Pascal Sanders; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  In Vitro Resistance Selection in Shigella flexneri by Azithromycin, Ceftriaxone, Ciprofloxacin, Levofloxacin, and Moxifloxacin.

Authors:  George P Allen; Kayla A Harris
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

3.  Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora.

Authors:  Maleck V Vasseur; Michel Laurentie; Jean-Guy Rolland; Agnès Perrin-Guyomard; Jérôme Henri; Aude A Ferran; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

4.  Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.

Authors:  Anne-Sylvie Kesteman; Aude A Ferran; Agnès Perrin-Guyomard; Michel Laurentie; Pascal Sanders; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

5.  Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infection.

Authors:  Aude A Ferran; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Vet Microbiol       Date:  2010-09-15       Impact factor: 3.293

6.  Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling.

Authors:  Xuesong Liu; Qingwen Yang; Yuying Fan; Yuanyi Du; Lei Lei; Dong Wang; Yun Liu
Journal:  BMC Vet Res       Date:  2021-06-09       Impact factor: 2.741

7.  In vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model.

Authors:  Bingxu Zhang; Xiaoyan Gu; Yafei Li; Xiaohong Li; Mengxiao Gu; Nan Zhang; Xiangguang Shen; Huanzhong Ding
Journal:  BMC Vet Res       Date:  2014-12-16       Impact factor: 2.741

8.  Prediction of Minocycline Activity in the Gut From a Pig Preclinical Model Using a Pharmacokinetic -Pharmacodynamic Approach.

Authors:  Quentin Vallé; Béatrice B Roques; Alain Bousquet-Mélou; David Dahlhaus; Felipe Ramon-Portugal; Véronique Dupouy; Delphine Bibbal; Aude A Ferran
Journal:  Front Microbiol       Date:  2021-07-09       Impact factor: 5.640

9.  Bacterial Species-Specific Activity of a Fluoroquinolone against Two Closely Related Pasteurellaceae with Similar MICs: Differential In Vitro Inoculum Effects and In Vivo Efficacies.

Authors:  Guillaume Lhermie; Farid El Garch; Pierre-Louis Toutain; Aude A Ferran; Alain Bousquet-Mélou
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

10.  Pharmacokinetics/pharmacodynamics of marbofloxacin in a Pasteurella multocida serious murine lung infection model.

Authors:  Ying Qu; Zhenzhen Qiu; Changfu Cao; Yan Lu; Meizhen Sun; Chaoping Liang; Zhenling Zeng
Journal:  BMC Vet Res       Date:  2015-12-02       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.